NasdaqGS:SNDXBiotechs
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Revuforj Data And New Managed Access Program
Conference spotlight and access program put Syndax Pharmaceuticals (SNDX) in focus
Syndax Pharmaceuticals (SNDX) is back on investors radar after positive Revuforj trial data, a new Managed Access Program with the World Orphan Drug Alliance, and a high profile slot at Guggenheim Securities Emerging Outlook Biotech Summit 2026.
See our latest analysis for Syndax Pharmaceuticals.
Despite a softer patch recently, with a 1 day share price return of a 3.12% decline and a 7 day share price return...